Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

FDA Approves Oncomine Dx Target Test Companion Diagnostic for Pralsetinib in RET+ NSCLC

September 11th 2020

The FDA has approved the Oncomine Dx Target Test as a companion diagnostic to identify patients with RET fusion–positive non¬–small lung cancer who are candidates to receive the recently approved targeted therapy pralsetinib.

PARP Inhibitor Therapy Options Are Transforming Landscape in Ovarian Cancer

September 4th 2020

PARP inhibitors have fundamentally changed our therapeutic algorithms in ovarian cancer, even as their use continues to evolve.

Liquid Biopsy Field Moves Forward But Faces Hurdles

September 2nd 2020

Technological advancements are rapidly expanding the potential uses for blood-based liquid biopsies, but broad clinical adoption in cancer care hinges on improving the knowledge base of practicing oncologists and gathering prospective data to validate assays.

Dr. Patel on the Safety Profile of Entrectinib in NTRK+ Solid Tumors

August 28th 2020

Manish R. Patel, DO, discusses the safety profile of entrectinib in NTRK fusion–positive solid tumors.

Dr. Pennell on the Evolution of Targeted Treatment in NSCLC

August 27th 2020

Nathan Pennell, MD, PhD, discusses the evolution of targeted therapies in the field of non–small cell lung cancer.

Dr. Pant on Targeting KRAS Mutations in Metastatic Solid Tumors

August 27th 2020

Shubham Pant, MD, discusses targeting KRAS mutations in advanced or metastatic solid tumors.

Increased Access to Germline Testing Needed in Prostate Cancer

August 27th 2020

Germline genetic testing is a key component of prostate cancer treatment, and broader testing criteria combined with reduced barriers to these tests could result in better informed care, including preventive surveillance, according to data from a recent study.

FDA Approves FoundationOne Liquid CDx for Solid Tumors

August 27th 2020

The FDA has approved the FoundationOne Liquid CDx, a liquid biopsy for all solid tumors with multiple companion diagnostic indications.

Dr. Shum on Emerging Targeted Therapies in EGFR-Mutant NSCLC

August 25th 2020

Elaine Shum, MD, discusses emerging targeted therapies in EGFR-mutant non–small cell lung cancer.

Dr. Partridge on the Role of Genomic Testing in Breast Cancer

August 25th 2020

Ann H. Partridge, MD, MPH, discusses the role of genomic testing in breast cancer.

FDA Grants Priority Review to Tepotinib for METex14-Altered Metastatic NSCLC

August 25th 2020

The FDA has granted a priority review designation to new drug application for tepotinib as a treatment for patient with metastatic non–small cell lung cancer whose tumors harbor a MET exon 14 skipping mutation identified via an FDA-approved test.

Companion Diagnostic, Targeted Therapy Approvals Rise in Tandem

August 23rd 2020

As precision medicine evolves in oncology, companion diagnostics are broadly and increasingly being adopted to guide treatment decisions, enabling clinicians to better and more precisely direct patients to therapies that best suit their unique genomic profiles.

Talking KRAS-Targeted Therapy in NSCLC With Dr. Levy

August 20th 2020

In our exclusive interview, Dr. Levy discusses the challenges of targeting KRAS and highlighted some of the investigational agents directed toward KRAS G12C mutations that have emerged in the NSCLC pipeline.

Presence of ctDNA, CTCs Independently Linked With Early-Stage TNBC Recurrence

August 19th 2020

A new, recently patented liquid biopsy device designed to detect small amounts of genetic and cellular material from tumors in the bloodstream of patients with early-stage, recurrent triple negative breast cancer, following neoadjuvant chemotherapy, has shown great accuracy and sensitivity.

Dr. Bunn on Targeting HER3 in NSCLC

August 18th 2020

Paul A. Bunn, Jr MD, discusses potentially targeting HER3 in non–small cell lung cancer.

Cell-Free DNA Analysis Could Aid in Detection, Optimal Management of Resistant Metastatic Prostate Cancer

August 18th 2020

Cell-free DNA–based androgen receptor locus alterations and enhancers correlated with metastatic prostate cancers determined to be resistant to AR-targeted therapies.

Dabrafenib Plus Trametinib Elicits Encouraging Responses in BRAF V600E-Mutant Tumors

August 13th 2020

The combination of dabrafenib and trametinib elicited favorable response rates in a mixed histology cohort of pretreated patients with solid tumors, lymphomas, and multiple myeloma whose tumors harbored a BRAF V600 mutation.

ADCs Are Poised to Enter HER2-Mutant NSCLC Armamentarium

August 10th 2020

Paul A. Bunn, Jr, MD, discusses antibody-drug conjugates and how they are on the cusp of being introduced into the treatment paradigm for patients with HER2-mutant non–small cell lung cancer.

FDA Approves Guardant360 CDx Liquid Biopsy for Comprehensive Genomic Profiling Across All Solid Cancers

August 7th 2020

The FDA has approved Guardant360® CDx for comprehensive genomic profiling in patients with any solid malignant cancer.

FDA Clears First MRD Assay for Chronic Lymphocytic Leukemia

August 6th 2020

The FDA has cleared the clonoSEQ® assay to identify and monitor minimal residual disease in blood or bone marrow from patients with chronic lymphocytic leukemia.